Date Title and Summary Additional Formats
Toggle Summary Altor BioScience Corporation and NantKwest Inc. Announce Co-Development Agreement to Advance Innovative Natural Killer Cell Combination Immunotherapies for the Treatment of Cancer
Cancer moonshot 2020 milestone: novel-novel combination of GPS Cancer guided cell based NK cell therapy and fusion proteins in QUILT trial CULVER CITY, Calif. & MIRAMAR, Fla. --(BUSINESS WIRE)--Oct. 4, 2016-- Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based
Toggle Summary Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2020-- Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of its next-generation natural
Toggle Summary Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- Brink Biologics, Inc. , a  NantKwest, Inc.
Toggle Summary Cheryl Cohen Appointed to NantKwest’s Board of Directors
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- NantKwest ( Nasdaq:NK ) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest , effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and
Toggle Summary Conkwest Announces $50M in Strategic Investments and Appoints Nantworks Founder, Dr. Patrick Soon-Shiong as Co-Chairman of the Board
SAN DIEGO (December 24, 2014) —Conkwest, Inc., the N atural K iller Cell Co mpany of the West, developing the proprietary Natural Killer (NK) cell-line platform, Neukoplast ® as an immuno-oncology therapeutic, announces that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and
Toggle Summary Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
SAN DIEGO (December 29, 2014) – Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast ® , a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D.
Toggle Summary Conkwest Files Registration Statement for Proposed Initial Public Offering
CARDIFF-BY-THE-SEA, Calif.--( BUSINESS WIRE )--Conkwest, Inc., a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, today announced that it has publicly
Toggle Summary Conkwest, Sorrento and NantWorks Announce Presentation at the 33rd Annual J. P. Morgan Healthcare Conference by Dr. Patrick Soon-Shiong
SAN DIEGO , Jan. 6, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast ® , a Natural Killer (NK) cell-line based therapy, announced
Toggle Summary Cord Blood Registry (CBR®) by Generate Life Sciences Partners With NantKwest to Develop COVID-19 Treatment
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest
Toggle Summary Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential “Vaccine” Protective Effect to be Highlighted in Oral Presentation at the 58th Annual Meeting of the American Society of Hematology
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory

Data Provided by Refinitiv. Minimum 15 minutes delayed.